Nanobiotix SA PARIS and CAMBRIDGE, Massachusetts, May 22, 2024 (GLOBE NEWSWIRE) – NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ”Company”), an advanced clinical-stage biotechnology company...
INVENTIVA Cash and cash equivalents at €11.0 million, short-term2 deposits at €0.1million, and long-term deposit at €19.1 million3 as of March 31, 2024, compared to €26.9...
SAN DIEGO, May 10, 2024–(BUSINESS WIRE)–Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company focused on harnessing the power of trained...
Achilles Therapeutics PLC – Provided interim Phase I/IIa update on clonal neoantigen-reactive T cells in advanced NSCLC and melanoma – – Evaluating the benefit of improved...
